Winsan (Chengdu) Medical Science And Technology Co (SHSE:600767) Risk Assessment

View and export this data going back to 1996. Start your Free Trial

What is Winsan (Chengdu) Medical Science And Technology Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Winsan (Chengdu) Medical Science And Technology Co is: No Data: Cannot be evaluated.

Competitive Comparison of Winsan (Chengdu) Medical Science And Technology Co's Risk Assessment

For the Health Information Services subindustry, Winsan (Chengdu) Medical Science And Technology Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Winsan (Chengdu) Medical Science And Technology Co's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Winsan (Chengdu) Medical Science And Technology Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Winsan (Chengdu) Medical Science And Technology Co's Risk Assessment falls into.

Winsan (Chengdu) Medical Science And Technology Co (SHSE:600767) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Winsan (Chengdu) Medical Science And Technology Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Winsan (Chengdu) Medical Science And Technology Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Winsan (Chengdu) Medical Science And Technology Co (SHSE:600767) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Winsan (Chengdu) Medical Science And Technology Co Ltd (SHSE:600767) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 69 Dongfang Road, Unit 1102-1104, Pudong New District, Shanghai, CHN, 200120

Website

http://www.winsan.cn

Winsan (Chengdu) Medical Science And Technology Co Ltd are engaged in technology development, technical consultation, and technical services in the field of public health and regional medical information. The company projects include Lishui Population Health Information PPP project which includes home pension, chronic disease management, remote diagnosis and treatment, medical insurance, and pharmacy services. It covers approximately 33 public health service agencies, 23 public hospitals, 193 township health centers, and 983 health service stations.

Executives

Ma Wei Guo	Director
Hua En Min	senior management
Jiang Hui Fang	senior management
Guan Wen Lian	Director
Luo Yong Jian	Director
Zhou Luo Man	Supervisors
Qian Min Hua	Director
Wu Ai Qun	Supervisors
Liang Yong Xin	Director

Winsan (Chengdu) Medical Science And Technology Co (SHSE:600767) Headlines

No Headlines